GLP1R and metabolic dysfunction-associated steatotic liver disease: In the liver, where the GLP‐1R is mainly expressed in sinusoid, in addition to targeting the islets and other means to reduce blood lipid levels for the treatment of MASLD, GLP‐1RA drugs also need target LSECs to improve the immune environment of the liver and rescue liver cell functions.